Status:
UNKNOWN
Neoadjuvant Chemotherapy Plus/Minus Surgery in Non-Small-Cell Lung Cancer (NSCLC) Stage IIIA/N2
Lead Sponsor:
Rigshospitalet, Denmark
Conditions:
Non-Small Cell Lung Cancer
Eligibility:
All Genders
18-75 years
Phase:
PHASE3
Brief Summary
Hypothesis is that surgery is of benefit in locally advanced NSCLC with N2 disease. Patients are randomised to surgery or not.
Detailed Description
Patients are after staging randomised to neoadj. chemotherapy followed by surgery followed by irradiation or to chemotherapy followed by irradiation. Endpoint is survival.
Eligibility Criteria
Inclusion
- Histologically verified NSCLC
- Stage IIIA/N2
- age 18-75
- Lung function test allowing surgery
- Mediastinoscopy performed
Exclusion
- Prior chemotherapy
- Prior irradiation
Key Trial Info
Start Date :
January 1 1998
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
January 1 2008
Estimated Enrollment :
406 Patients enrolled
Trial Details
Trial ID
NCT00273494
Start Date
January 1 1998
End Date
January 1 2008
Last Update
May 22 2008
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Dept. Oncology, Rigshospitalet
Copenhagen, Copenhagen, Denmark, 2100